Skip to main content

An autograph of Jamaican sprinter Asafa Powell is pictured inside the hotel where Powell stayed in Lignano Sabbiadoro, northern Italy on July 16, 2013. Mr. Powell and fellow sprinter Sherone Simpson have acknowledged that they had tested positive for a banned stimulant, and Mr. Powell’s agent blamed the test result on Chris Xuereb, an athletic therapist who had worked off and on for several years at the Institute of Sports Medicine and Wellness Centre in Toronto.

ALESSANDRO GAROFALO/REUTERS

A baffling aspect about the alleged doping scandal that has engulfed two Jamaican sprinters and their Canadian trainer is that it involved a banned drug that takes little effort to expose.

Oxilofrine, also known as methylsynephrine, is a stimulant that can be found in weight-loss supplements, said Christiane Ayotte, head of the INRS-Institut Armand-Frappier doping lab, a facility accredited by the World Anti-Doping Agency.

It has become more popular as an ingredient after another stimulant, ephedrine, which used to be commercially available, became a controlled substance, she said.

Story continues below advertisement

In recent years, oxilofrine doping cases have been increasing, from about five cases annually to 15 to 20, Dr. Ayotte said.

"It's ridiculously easy to detect," she said, adding that she was baffled why athletes would use it.

The supplements can be ordered online and oxilofrine itself can also be purchased in bulk from China, she said. "People shouldn't think they'll find it in their breakfast cereal or in regular food. You really have to look for it."

There have been civil suits that allege that supplement manufacturers failed to properly list oxilofrine as an ingredient.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies